dehydroabietylamine profile

Dehydroabietylamine (DHA) is a naturally occurring diterpene amine found in various plants, including Abies species (fir trees). It has been shown to possess a range of biological activities, including antimicrobial, anti-inflammatory, and anticancer properties. Its synthesis involves several steps, starting from abietic acid, a common resin acid found in conifers. The amine group is typically introduced through a reductive amination process. DHA's effects are attributed to its ability to interact with various biological targets, including enzymes, receptors, and cell membranes. Research on DHA focuses on its potential therapeutic applications, particularly in the treatment of bacterial infections, inflammatory disorders, and cancer. Studies have investigated its mechanism of action, its pharmacokinetic properties, and its potential for clinical development.'

dehydroabietylamine: has antimalarial activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	62034
CHEMBL ID	70488
CHEBI ID	93086
SCHEMBL ID	27863
MeSH ID	M000609334

Synonym
MLS002207102
smr001306713
4-12-00-03005 (beilstein handbook reference)
33289o147p ,
nsc 2955
unii-33289o147p
BRD-K62289640-003-01-9
dehydroabietylamine
podocarpa-8,13-trien-15-amine, 13-isopropyl-
nsc-2955
1-phenanthrenemethanamine,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, [1r-(1.alpha.,4a.beta.,10a.alpha.)]-
1446-61-3
nsc2955
brn 3084620
epa pesticide chemical code 004206
13-isopropylpodocarpa-8,11,13-trien-15-amine
hsdb 5665
1-phenanthrenemethanamine, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1r,4as,10ar)-
1-phenanthrenemethanamine, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1r-(1alpha,4abeta,10aalpha))-
einecs 215-899-7
caswell no. 276
(+)-dehydroabietylamine, technical grade, 60%
CHEMBL70488 ,
(+)-dehydroabietylamine
dehydroabiethylamine
D1180
D1588
((1r,4as,10ar)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl)methanamine
AKOS015914070
1-phenanthrenemethanamine 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-,(1r,4as,10ar)-
dehydroabietylamine [hsdb]
SCHEMBL27863
JVVXZOOGOGPDRZ-SLFFLAALSA-N
W-108153
DTXSID2041834
CS-W005629
CHEBI:93086
(+)-dehydroabietylamine; >95%
DS-18554
Q15409408
lylamine
bdbm50217007
A884771
dehydroabietylamine (>80%)
HY-W005629
1-[(1r,4as,10ar)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methanamine
EN300-7409771
Z2216889331
1078140-96-1
rel-((1r,4as,10ar)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl)methanamine

Excerpt	Reference	Relevance
"This review not only gives a summary of the most important findings on the cytotoxic behavior of DAderived compounds but also shows some drawbacks of these compounds, such low bioavailability and/or poor solubility of several derivatives of DA."	( Cytotoxic Dehydroabietylamine Derived Compounds. Al-Harrasi, A; Csuk, R; Wiemann, J, 2020)	0.96

Excerpt	Relevance	Reference
" The dosage of CTAB should be moderate; too high or too low will decay the ordering degree of the lamellar structure."	( Synthesis of ordered lamellar supermicroporous silica with rigid neutral and long-chain cationic composite templating route. Chen, S; Fan, G; Liao, S; Si, H; Wang, P; Wang, Z, 2019)	0.51

Class	Description
diterpenoid	Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
TDP1 protein	Homo sapiens (human)	Potency	29.0929	0.0008	11.3822	44.6684	AID686978; AID686979
IDH1	Homo sapiens (human)	Potency	23.1093	0.0052	10.8652	35.4813	AID686970
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	8.1995	0.0041	9.9848	25.9290	AID504444
geminin	Homo sapiens (human)	Potency	20.5962	0.0046	11.3741	33.4983	AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)	IC50 (µMol)	9.5000	0.0005	1.8909	9.5000	AID162967
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)	IC50 (µMol)	9.5000	0.0650	3.1299	9.5000	AID162967
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)	IC50 (µMol)	9.5000	0.0260	3.5666	9.5000	AID162967
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)	IC50 (µMol)	9.5000	0.0210	3.5860	9.5000	AID162967
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
glucose metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
cell population proliferation	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
regulation of glucose metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathway	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
protein phosphorylation	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
glucose metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
regulation of gluconeogenesis	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
regulation of pH	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
insulin receptor signaling pathway	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
regulation of cellular ketone metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
regulation of glucose metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
cellular response to nutrient	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
cellular response to reactive oxygen species	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
glucose homeostasis	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
regulation of calcium-mediated signaling	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
protein phosphorylation	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
regulation of glucose metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
peptidyl-serine phosphorylation	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
peroxisome proliferator activated receptor signaling pathway	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
cellular response to fatty acid	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathway	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
regulation of reactive oxygen species metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
protein phosphorylation	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
regulation of pH	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
insulin receptor signaling pathway	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
cellular response to starvation	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
regulation of acetyl-CoA biosynthetic process from pyruvate	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
regulation of cellular ketone metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
regulation of glucose metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
regulation of fatty acid biosynthetic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
glucose homeostasis	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
response to starvation	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
regulation of bone resorption	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
regulation of fatty acid oxidation	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
cellular response to fatty acid	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
reactive oxygen species metabolic process	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
negative regulation of anoikis	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
protein phosphorylation	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein kinase activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
protein binding	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
ATP binding	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
protein kinase activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
protein binding	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
ATP binding	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
protein homodimerization activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
protein kinase activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
protein serine/threonine kinase activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
protein binding	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
ATP binding	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
protein kinase activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
pyruvate dehydrogenase (acetyl-transferring) kinase activity	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
protein binding	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
ATP binding	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
mitochondrial matrix	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
mitochondrion	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial	Homo sapiens (human)
nucleoplasm	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
mitochondrion	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
mitochondrial matrix	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
cytosol	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
pyruvate dehydrogenase complex	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
mitochondrion	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial	Homo sapiens (human)
nucleolus	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
mitochondrion	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
mitochondrial matrix	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
mitochondrion	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial	Homo sapiens (human)
mitochondrial matrix	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
mitochondrion	[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (87)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1352793	Antiproliferative activity against human MCF7 cells after 36 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID131122	In vivo activity in a diabetic mouse at a dose of 30 umol/kg/day on day1 after 6 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1246299	Cytotoxicity against HEK293 cells at <= 50 uM after 72 hrs by CellTiter-Glo assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID1299557	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahuen C2C4 amastigotes	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Abietane-Type Diterpenoid Amides with Highly Potent and Selective Activity against Leishmania donovani and Trypanosoma cruzi.
AID131254	In vivo activity in a diabetic mouse at a dose of 300 umol/kg/day on day1 after 6 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID755529	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID1637807	Antineoplastic activity against human MCF7 cells measured after 36 hrs by MTT assay	2018	MedChemComm, Dec-01, Volume: 9, Issue:12	Synthesis and potential antineoplastic activity of dehydroabietylamine imidazole derivatives.
AID162967	In vitro inhibitory activity against pyruvate dehydrogenase kinase was determined	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1637806	Antineoplastic activity against human HepG2 cells measured after 36 hrs by MTT assay	2018	MedChemComm, Dec-01, Volume: 9, Issue:12	Synthesis and potential antineoplastic activity of dehydroabietylamine imidazole derivatives.
AID755527	Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID1352799	Induction of apoptosis in human HepG2 cells assessed as viable cells at 0.1 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 83.13%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID1406741	Selectivity index, ratio of EC50 for mouse NIH/3T3 cells to EC50 for human MCF7 cells	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Syntheses of C-ring modified dehydroabietylamides and their cytotoxic activity.
AID1637809	Cytotoxicity against HUVEC measured after 36 hrs by MTT assay	2018	MedChemComm, Dec-01, Volume: 9, Issue:12	Synthesis and potential antineoplastic activity of dehydroabietylamine imidazole derivatives.
AID1352798	Induction of apoptosis in human HepG2 cells assessed as necrotic cells at 0.1 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 1.86%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID1406740	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Syntheses of C-ring modified dehydroabietylamides and their cytotoxic activity.
AID1406738	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Syntheses of C-ring modified dehydroabietylamides and their cytotoxic activity.
AID755549	Hemolytic activity in mouse RBC at 100 uM after 1 hr by ELISA relative to control	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID1352797	Induction of apoptosis in human HepG2 cells assessed as late apoptotic cells at 0.1 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 7.09%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID755530	Induction of apoptosis in human EJ cells assessed as decrease in procaspase-3 level at 5 uM after 24 hrs by Western blot analysis	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID755544	Induction of apoptosis in human EJ cells assessed as formation of apoptotic bodies at 5 uM after 24 hrs by Hoechst 33342 staining-based confocal microscopic analysis	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID131124	In vivo activity in a diabetic mouse at a dose of 300 umol/kg/day on day 3 after 4 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID755540	Induction of apoptosis in human EJ cells assessed as early apoptotic cells at 5 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.01 to 0.04%)	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID1637805	Antineoplastic activity against human HeLa cells measured after 36 hrs by MTT assay	2018	MedChemComm, Dec-01, Volume: 9, Issue:12	Synthesis and potential antineoplastic activity of dehydroabietylamine imidazole derivatives.
AID131121	In vivo activity in a diabetic mouse at a dose of 30 umol/kg/day on day1 after 4 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID131099	In vivo activity in a diabetic mouse at a dose of 100 umol/kg/day on day 3 after 2 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1637824	Drug internalization in human HeLa cells at 100 nM incubated for 2 hrs at 4 degC by confocal fluorescence imaging analysis	2018	MedChemComm, Dec-01, Volume: 9, Issue:12	Synthesis and potential antineoplastic activity of dehydroabietylamine imidazole derivatives.
AID1406737	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Syntheses of C-ring modified dehydroabietylamides and their cytotoxic activity.
AID755543	Induction of apoptosis in human EJ cells assessed as nuclear condensation at 5 uM after 24 hrs by Hoechst 33342 staining-based confocal microscopic analysis	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID1352802	Induction of apoptosis in human HepG2 cells assessed as necrotic cells at 1 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 1.86%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID755532	Induction of apoptosis in human EJ cells assessed as decrease in procaspase-9 level at 5 uM after 24 hrs by Western blot analysis	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID755553	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID755531	Induction of apoptosis in human EJ cells assessed as caspase-8 activation at 5 uM after 24 hrs by Western blot analysis	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID755547	Induction of necrosis in human EJ cells assessed as disruption of membrane integrity at 15 uM after 1 hr by propidium iodide uptake assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID1352801	Induction of apoptosis in human HepG2 cells assessed as late apoptotic cells at 1 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 7.09%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID755528	Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID131104	In vivo activity in a diabetic mouse at a dose of 100 umol/kg/day on day1 after 6 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1299556	Cytotoxicity against rat L6 cells after 72 hrs by AlamarBlue dye based fluorimetric method	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Abietane-Type Diterpenoid Amides with Highly Potent and Selective Activity against Leishmania donovani and Trypanosoma cruzi.
AID1352800	Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells at 1 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 7.92%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID1352792	Antiproliferative activity against human HepG2 cells after 36 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID1352796	Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells at 0.1 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 7.92%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID1637808	Antineoplastic activity against human A549 cells measured after 36 hrs by MTT assay	2018	MedChemComm, Dec-01, Volume: 9, Issue:12	Synthesis and potential antineoplastic activity of dehydroabietylamine imidazole derivatives.
AID131126	In vivo activity in a diabetic mouse at a dose of 300 umol/kg/day on day1 after 2 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1299548	Antileishmanial activity against axenic amastigotes of Leishmania donovani MHOM/SD/1962/1S-Cl2d infected in human THP1 cells assessed as parasite growth inhibition at 50 uM after 24 hrs by AlamarBlue viability assay	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Abietane-Type Diterpenoid Amides with Highly Potent and Selective Activity against Leishmania donovani and Trypanosoma cruzi.
AID1406736	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Syntheses of C-ring modified dehydroabietylamides and their cytotoxic activity.
AID1352794	Antiproliferative activity against human A549 cells after 36 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID755551	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID755539	Induction of apoptosis in human EJ cells assessed as viable cells at 5 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 99.6%)	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID1246298	Antiproliferative activity against human triple-negative MDA-MB-231 cells at <= 50 uM after 72 hrs by CellTiter-Glo assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
AID1299555	Antitrypanosomal activity against trypomastigote form of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometric method	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Abietane-Type Diterpenoid Amides with Highly Potent and Selective Activity against Leishmania donovani and Trypanosoma cruzi.
AID131118	In vivo activity in a diabetic mouse at a dose of 30 umol/kg/day on day 3 after 4 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1352791	Antiproliferative activity against human HeLa cells after 36 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID755533	Induction of apoptosis in human EJ cells assessed as increase in cytosolic cytochrome c level at 5 uM after 24 hrs by Western blot analysis	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID755542	Induction of apoptosis in human EJ cells assessed as necrotic cells at 5 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.28 to 0.30%)	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID1352795	Cytotoxicity against HUVEC assessed as reduction in cell viability after 36 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID1406739	Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine-B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Syntheses of C-ring modified dehydroabietylamides and their cytotoxic activity.
AID131102	In vivo activity in a diabetic mouse at a dose of 100 umol/kg/day on day1 after 2 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1352803	Induction of apoptosis in human HepG2 cells assessed as viable cells at 1 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 83.13%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID131100	In vivo activity in a diabetic mouse at a dose of 100 umol/kg/day on day 3 after 4 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1318782	Cytotoxicity against mouse J774 cells assessed as reduction of cell viability after 48 hrs by resazurin dye-based fluorometric method	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and antileishmanial activity of C7- and C12-functionalized dehydroabietylamine derivatives.
AID1352807	Induction of apoptosis in human HepG2 cells assessed as viable cells at 10 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 83.13%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID1352804	Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells at 10 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 7.92%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID755541	Induction of apoptosis in human EJ cells assessed as late apoptotic cells at 5 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.08 to 0.22%)	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID131253	In vivo activity in a diabetic mouse at a dose of 300 umol/kg/day on day1 after 4 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID755552	Cytotoxicity against human EJ cells assessed as cell death at 10 to 20 uM after 1 hr by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Anticancer effects of a novel class rosin-derivatives with different mechanisms.
AID1352805	Induction of apoptosis in human HepG2 cells assessed as late apoptotic cells at 10 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 7.09%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID131117	In vivo activity in a diabetic mouse at a dose of 30 umol/kg/day on day 3 after 2 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID90950	In vitro effective concentration in normal human dermal fibroblasts; Inactive	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1352806	Induction of apoptosis in human HepG2 cells assessed as necrotic cells at 10 ug/ml after 24 hrs by Annexin V/propidium iodide staining based flow cytometry (Rvb = 1.86%)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.
AID131103	In vivo activity in a diabetic mouse at a dose of 100 umol/kg/day on day1 after 4 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID131123	In vivo activity in a diabetic mouse at a dose of 300 umol/kg/day on day 3 after 2 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID131119	In vivo activity in a diabetic mouse at a dose of 30 umol/kg/day on day 3 after 6 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1406735	Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Syntheses of C-ring modified dehydroabietylamides and their cytotoxic activity.
AID131125	In vivo activity in a diabetic mouse at a dose of 300 umol/kg/day on day 3 after 6 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID131120	In vivo activity in a diabetic mouse at a dose of 30 umol/kg/day on day1 after 2 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID131101	In vivo activity in a diabetic mouse at a dose of 100 umol/kg/day on day 3 after 6 hr	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).
AID1246300	Cytotoxicity against human HepG2 cells at <= 50 uM after 72 hrs by CellTiter-Glo assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (3.33)	18.2507
2000's	1 (3.33)	29.6817
2010's	19 (63.33)	24.3611
2020's	9 (30.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (3.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	29 (96.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	2.6	1	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.11	1	aromatic ether; nitrile; polyether; tertiary amino compound
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	2.11	1	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
cetyltrimethylammonium ion Cetrimonium: Cetyltrimethylammonium compound whose salts and derivatives are used primarily as topical antiseptics.. cetyltrimethylammonium ion : A quaternary ammonium ion in which the substituents on nitrogen are one hexadecyl and three methyl groups.	2.21	1	quaternary ammonium ion
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.17	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	2.13	1	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
dichloroacetic acid [no description available]	2	1	monocarboxylic acid; organochlorine compound	astringent; marine metabolite
2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester [no description available]	2.11	1	piperidines
nandrolone Nandrolone: C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position.. nandrolone : A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.	2	1	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid	human metabolite
abietic acid abietic acid : An abietane diterpenoid that is abieta-7,13-diene substituted by a carboxy group at position 18.	2.74	3	abietane diterpenoid; monocarboxylic acid	plant metabolite
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	2.13	1	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	2.13	1	C-nitro compound; imidazoles	antitubercular agent
sodium hydroxide Sodium Hydroxide: A highly caustic substance that is used to neutralize acids and make sodium salts. (From Merck Index, 11th ed)	2.21	1	alkali metal hydroxide
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	2.13	1	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
closantel closantel: structure. N-{5-chloro-4-[(4-chlorophenyl)(cyano)methyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide : An aromatic amide resulting from the formal condensation of the carboxy group of 3,5-diiodosalicylic acid with the amino group of aniline substituted at positions 2, 4, and 5 by methyl, (4-chlorophenyl)(cyano)methyl, and methyl groups respectively.. closantel : A racemate comprising equimolar amounts of (R)- and (S)-clostanel. An anthelmintic, it is used (as the dihydrate of the sodium salt) in veterinary medicine for the treatment of fluke and nematode infections.	2.13	1	aromatic amide; monocarboxylic acid amide; monochlorobenzenes; nitrile; organoiodine compound; phenols
staurosporine [no description available]	2.11	1	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
betulinic acid [no description available]	2.17	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
salvin salvin: a biocyclic diterpenoid; from sage and rosemary (Lamiaceae)	2.11	1	abietane diterpenoid; carbotricyclic compound; catechols; monocarboxylic acid	angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; food preservative; HIV protease inhibitor; plant metabolite
podocarpic acid podocarpic acid: structure. podocarpic acid : An abietane diterpenoid lacking the isopropyl substituent with an aromatic C-ring and a hydroxy group at the 12-position.	2	1	abietane diterpenoid
dehydroabietic acid dehydroabietic acid: major aquatic toxicant in effluent of pulp and paper mills. dehydroabietic acid : An abietane diterpenoid that is abieta-8,11,13-triene substituted at position 18 by a carboxy group.. dehydroabietate : A monocarboxylic acid anion that is the conjugate base of dehydroabietic acid, obtained by deprotonation of the carboxy group.	2.5	2	abietane diterpenoid; carbotricyclic compound; monocarboxylic acid	allergen; metabolite
cd 437 CD 437: selective for retinoic acid receptors gamma. CD437 : A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells.	2.13	1	adamantanes; monocarboxylic acid; naphthoic acid; phenols	apoptosis inducer; retinoic acid receptor gamma agonist
pimaric acid pimaric acid: RN given refers to (D)-isomer; structure	2.11	1	diterpenoid
carnosol carnosol: isolated from Lepechinia hastata	2.11	1	diterpenoid
ferruginol ferruginol: structure in first source. ferruginol : An abietane diterpenoid that is abieta-8,11,13-triene substituted by a hydroxy group at positions 12.	7.81	3	abietane diterpenoid; carbotricyclic compound; meroterpenoid; phenols	antibacterial agent; antineoplastic agent; plant metabolite; protective agent
quinine [no description available]	2.08	1	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.13	1	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
norethisterone-3-oxime [no description available]	2	1
levomepromazine maleate 6-hydroxysalvinolone: from Salvia chorassanica; structure in first source	2.13	1
chamobtusin a chamobtusin A: from Chamaecyparis obtusa cv. tetragon; structure in first source	7.13	1
sybr green i SYBR Green I: binds to double stranded DNA of less than 20 pg following agarose or polyacrylamide gel electrophoresis; excited at 497 nm and emits at 520 nm. SYBR Green I : A benzothiazolium ion resulting from the methylation of the nitrogen of the benzothiazole group of N-[4-(1,3-benzothiazol-2-ylmethylene)-1-phenyl-1,4-dihydroquinolin-2-yl]-N',N'-dimethyl-N-propylpropane-1,3-diamine. A cationic unsymmetrical cyanine dye that binds to double-stranded DNA and is used as a nucleic acid stain in molecular biology.	2.11	1	benzothiazolium ion; cyanine dye; quinolines; tertiary amine	fluorescent dye

Condition	Relationship Strength	Studies
Alloxan Diabetes [description not available]	2	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.11	1
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.11	1
Leishmania Infection [description not available]	2.13	1
American Trypanosomiasis [description not available]	2.13	1
Leishmaniasis A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).	2.13	1
Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.	2.13	1
Benign Neoplasms [description not available]	4.04	4
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.04	4
Hepatocellular Carcinoma [description not available]	7.61	2
Cancer of Liver [description not available]	2.61	2
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.61	2
Liver Neoplasms Tumors or cancer of the LIVER.	2.61	2
Breast Cancer [description not available]	2.41	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.41	1
Kahler Disease [description not available]	2.31	1
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	2.31	1
Infections, Pseudomonas [description not available]	2.25	1
Infections, Staphylococcal [description not available]	2.25	1
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	2.25	1
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	2.25	1

dehydroabietylamine

Description

Cross-References

Synonyms (50)

Research Excerpts

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Biological Processes (27)

Molecular Functions (6)

Ceullar Components (6)

Bioassays (87)

Research

Studies (30)

Market Indicators

Research Demand Index: 29.31

Study Types

dehydroabietylamine

Description

Cross-References

Synonyms (50)

Research Excerpts

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Biological Processes (27)

Molecular Functions (6)

Ceullar Components (6)

Bioassays (87)

Research

Studies (30)

Market Indicators

Research Demand Index: 29.31

Study Types

Related Drugs (30)

Related Conditions (24)